STOCK TITAN

[Form 4] UNITED THERAPEUTICS Corp Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

United Therapeutics (UTHR) reported insider transactions by its Chairperson & CEO under a Rule 10b5-1 plan. On 10/27/2025 and 10/28/2025, the insider exercised 4,000 stock options each day at an exercise price of $120.26 per share and sold the resulting shares in open-market trades.

Sales on 10/27 were 1,000 shares at $411.9545, 1,814 at $414.4191, and 1,186 at $420.2887. Sales on 10/28 were 1,991 at $413.5798, 509 at $415.02, and 1,500 at $417.915. Following these transactions, direct holdings were 130 shares. Indirect holdings include 166 by spouse, 324,518 and 257,117 by family trusts, and 45,596 and 15,962 via spouse-related trusts.

The filing states the 10b5-1 plan was entered on May 2, 2025 and will continue until the earlier of exhaustion of a tranche of 294,000 options expiring March 15, 2026 or December 31, 2025.

United Therapeutics (UTHR) ha riportato operazioni di insider da parte del proprio presidente e CEO nell’ambito di un piano Rule 10b5-1. Il 27/10/2025 e il 28/10/2025, l’insider ha esercitato 4.000 stock option ogni giorno a un prezzo di esercizio di $120.26 per azione e ha venduto le azioni risultanti in operazioni sul mercato aperto.

Le vendite del 27/10 sono state 1.000 azioni a $411.9545, 1.814 a $414.4191, e 1.186 a $420.2887. Le vendite del 28/10 sono state 1.991 a $413.5798, 509 a $415.02, e 1.500 a $417.915. A seguito di queste operazioni, le partecipazioni dirette ammontano a 130 azioni. Le partecipazioni indirette includono 166 da parte del coniuge, 324.518 e 257.117 tramite trust familiari, e 45.596 e 15.962 tramite trust correlati al coniuge.

Il deposito indica che il piano 10b5-1 è stato stipulato il 2 maggio 2025 e continuerà fino all’emergere della prima delle seguenti condizioni: esaurimento di una tranche di 294.000 opzioni in scadenza il 15 marzo 2026 oppure il 31 dicembre 2025.

United Therapeutics (UTHR) informó transacciones de insiders por parte de su presidente y CEO bajo un plan Rule 10b5-1. El 27/10/2025 y el 28/10/2025, el insider ejerció 4.000 opciones de acciones cada día a un precio de ejercicio de $120.26 por acción y vendió las acciones resultantes en operaciones en el mercado abierto.

Las ventas del 27/10 fueron 1.000 acciones a $411.9545, 1.814 a $414.4191, y 1.186 a $420.2887. Las ventas del 28/10 fueron 1.991 a $413.5798, 509 a $415.02, y 1.500 a $417.915. Después de estas operaciones, las participaciones directas son 130 acciones. Las participaciones indirectas incluyen 166 por parte del cónyuge, 324.518 y 257.117 por fideicomisos familiares, y 45.596 y 15.962 a través de fideicomisos relacionados con el cónyuge.

La presentación indica que el plan 10b5-1 se firmó el 2 de mayo de 2025 y continuará hasta la primera de las siguientes condiciones: agotamiento de una tranche de 294.000 opciones con vencimiento el 15 de marzo de 2026 o el 31 de diciembre de 2025.

United Therapeutics (UTHR) 는 이사회 의장 겸 CEO 아래 Rule 10b5-1 계획에 따른 내부자 거래를 보고했습니다. 2025/10/272025/10/28에 내부자가 매일 4,000 주의 주식매수를 행사했고, 행사 가격은 주당 $120.26이며 그로 얻은 주식을 공개시장 매매로 팔았습니다.

10/27의 매도는 1,000 주가 $411.9545, 1,814 주가 $414.4191, 1,186 주가 $420.2887이었습니다. 10/28의 매도는 1,991 주가 $413.5798, 509 주가 $415.02, 1,500 주가 $417.915였습니다. 이러한 거래 후 직접 보유 주식은 130 주로 줄었습니다. 간접 보유에는 배우자에 의한 166, 가족 신탁을 통한 324,518257,117, 배우자 관련 신탁을 통한 45,59615,962가 포함됩니다.

신고에 따르면 10b5-1 계획은 2025년 5월 2일에 체결되었으며, 2026년 3월 15일 만료되는 294,000개 옵션의 소진 또는 2025년 12월 31일 중 먼저 도래하는 시점까지 계속될 예정입니다.

United Therapeutics (UTHR) a signalé des transactions d’initiés par son président et PDG dans le cadre d’un plan Rule 10b5-1. Le 27/10/2025 et le 28/10/2025, l’initié a exercé 4 000 options d’achat d’actions chaque jour à un prix d’exercice de $120,26 par action et a vendu les actions résultantes lors d’opérations sur le marché libre.

Les ventes du 27/10 étaient 1 000 actions à $411,9545, 1 814 à $414,4191, et 1 186 à $420,2887. Les ventes du 28/10 étaient 1 991 à $413,5798, 509 à $415,02, et 1 500 à $417,915. À la suite de ces transactions, les détentions directes atteignent 130 actions. Les détentions indirectes incluent 166 par le conjoint, 324 518 et 257 117 par des fiducies familiales, et 45 596 et 15 962 via des fiducies liées au conjoint.

Le dépôt indique que le plan 10b5-1 a été conclu le 2 mai 2025 et se poursuivra jusqu’à la première des condition suivantes: l’épuisement d’une tranche de 294 000 options arrivant à échéance le 15 mars 2026 ou le 31 décembre 2025.

United Therapeutics (UTHR) meldete Insider-Transaktionen durch seinen Vorsitzenden und CEO im Rahmen eines Rule 10b5-1-Plans. Am 27.10.2025 und 28.10.2025 übte der Insider 4.000 Aktioptionsscheine pro Tag zu einem Ausübungspreis von $120,26 pro Aktie aus und verkaufte die resultierenden Aktien in Open-Market-Transaktionen.

Verkäufe am 27.10 waren 1.000 Aktien zu $411,9545, 1.814 zu $414,4191 und 1.186 zu $420,2887. Verkäufe am 28.10 waren 1.991 zu $413,5798, 509 zu $415,02 und 1.500 zu $417,915. Nach diesen Transaktionen belief sich der direkte Anteil auf 130 Aktien. Indirekte Anteile umfassen 166 durch den Ehepartner, 324.518 und 257.117 durch Familienstiftungen sowie 45.596 und 15.962 über Ehepartner-bezogene Trusts.

Die Einreichung besagt, dass der 10b5-1-Plan am 2. Mai 2025 abgeschlossen wurde und bis zum früheren der beiden Ereignisse fortgeführt wird: Auslaufen eines Tranches von 294.000 Optionen, fällig am 15. März 2026, oder 31. Dezember 2025.

United Therapeutics (UTHR) قد أبلغت عن معاملات داخلية من قبل رئيسها ومهندسها التنفيذي بموجب خطة Rule 10b5-1. في 27/10/2025 و28/10/2025، قام الداخل بتمرين 4,000 خيار أسهم كل يوم عند سعر ممارسة قدره $120.26 للسهم وباع الأسهم الناتجة في معاملات في السوق المفتوح.

كانت المبيعات في 27/10 1,000 سهم بسعر $411.9545، و1,814 بسعر $414.4191، و1,186 بسعر $420.2887. وكانت مبيعات 28/10 1,991 بسعر $413.5798، و509 بسعر $415.02، و1,500 بسعر $417.915. بعد هذه المعاملات، لم يعد يمتلك الأسهم بشكل مباشر 130 سهماً. وتتضمن الملكيات غير المباشرة 166 من قبل الزوج، و324,518 و257,117 عن طريق trusts العائلية، و45,596 و15,962 عبر trusts متعلقة بالزوج.

تنص الوثيقة على أن خطة 10b5-1 تم دخولها في 2 مايو 2025 وستستمر حتى إما نفاد شريحة من 294,000 خيار منتهية صلاحيتها في 15 مارس 2026 أو 31 ديسمبر 2025، أيهما يأتي أولاً.

Positive
  • None.
Negative
  • None.

Insights

Analyzing...

United Therapeutics (UTHR) ha riportato operazioni di insider da parte del proprio presidente e CEO nell’ambito di un piano Rule 10b5-1. Il 27/10/2025 e il 28/10/2025, l’insider ha esercitato 4.000 stock option ogni giorno a un prezzo di esercizio di $120.26 per azione e ha venduto le azioni risultanti in operazioni sul mercato aperto.

Le vendite del 27/10 sono state 1.000 azioni a $411.9545, 1.814 a $414.4191, e 1.186 a $420.2887. Le vendite del 28/10 sono state 1.991 a $413.5798, 509 a $415.02, e 1.500 a $417.915. A seguito di queste operazioni, le partecipazioni dirette ammontano a 130 azioni. Le partecipazioni indirette includono 166 da parte del coniuge, 324.518 e 257.117 tramite trust familiari, e 45.596 e 15.962 tramite trust correlati al coniuge.

Il deposito indica che il piano 10b5-1 è stato stipulato il 2 maggio 2025 e continuerà fino all’emergere della prima delle seguenti condizioni: esaurimento di una tranche di 294.000 opzioni in scadenza il 15 marzo 2026 oppure il 31 dicembre 2025.

United Therapeutics (UTHR) informó transacciones de insiders por parte de su presidente y CEO bajo un plan Rule 10b5-1. El 27/10/2025 y el 28/10/2025, el insider ejerció 4.000 opciones de acciones cada día a un precio de ejercicio de $120.26 por acción y vendió las acciones resultantes en operaciones en el mercado abierto.

Las ventas del 27/10 fueron 1.000 acciones a $411.9545, 1.814 a $414.4191, y 1.186 a $420.2887. Las ventas del 28/10 fueron 1.991 a $413.5798, 509 a $415.02, y 1.500 a $417.915. Después de estas operaciones, las participaciones directas son 130 acciones. Las participaciones indirectas incluyen 166 por parte del cónyuge, 324.518 y 257.117 por fideicomisos familiares, y 45.596 y 15.962 a través de fideicomisos relacionados con el cónyuge.

La presentación indica que el plan 10b5-1 se firmó el 2 de mayo de 2025 y continuará hasta la primera de las siguientes condiciones: agotamiento de una tranche de 294.000 opciones con vencimiento el 15 de marzo de 2026 o el 31 de diciembre de 2025.

United Therapeutics (UTHR) 는 이사회 의장 겸 CEO 아래 Rule 10b5-1 계획에 따른 내부자 거래를 보고했습니다. 2025/10/272025/10/28에 내부자가 매일 4,000 주의 주식매수를 행사했고, 행사 가격은 주당 $120.26이며 그로 얻은 주식을 공개시장 매매로 팔았습니다.

10/27의 매도는 1,000 주가 $411.9545, 1,814 주가 $414.4191, 1,186 주가 $420.2887이었습니다. 10/28의 매도는 1,991 주가 $413.5798, 509 주가 $415.02, 1,500 주가 $417.915였습니다. 이러한 거래 후 직접 보유 주식은 130 주로 줄었습니다. 간접 보유에는 배우자에 의한 166, 가족 신탁을 통한 324,518257,117, 배우자 관련 신탁을 통한 45,59615,962가 포함됩니다.

신고에 따르면 10b5-1 계획은 2025년 5월 2일에 체결되었으며, 2026년 3월 15일 만료되는 294,000개 옵션의 소진 또는 2025년 12월 31일 중 먼저 도래하는 시점까지 계속될 예정입니다.

United Therapeutics (UTHR) a signalé des transactions d’initiés par son président et PDG dans le cadre d’un plan Rule 10b5-1. Le 27/10/2025 et le 28/10/2025, l’initié a exercé 4 000 options d’achat d’actions chaque jour à un prix d’exercice de $120,26 par action et a vendu les actions résultantes lors d’opérations sur le marché libre.

Les ventes du 27/10 étaient 1 000 actions à $411,9545, 1 814 à $414,4191, et 1 186 à $420,2887. Les ventes du 28/10 étaient 1 991 à $413,5798, 509 à $415,02, et 1 500 à $417,915. À la suite de ces transactions, les détentions directes atteignent 130 actions. Les détentions indirectes incluent 166 par le conjoint, 324 518 et 257 117 par des fiducies familiales, et 45 596 et 15 962 via des fiducies liées au conjoint.

Le dépôt indique que le plan 10b5-1 a été conclu le 2 mai 2025 et se poursuivra jusqu’à la première des condition suivantes: l’épuisement d’une tranche de 294 000 options arrivant à échéance le 15 mars 2026 ou le 31 décembre 2025.

United Therapeutics (UTHR) meldete Insider-Transaktionen durch seinen Vorsitzenden und CEO im Rahmen eines Rule 10b5-1-Plans. Am 27.10.2025 und 28.10.2025 übte der Insider 4.000 Aktioptionsscheine pro Tag zu einem Ausübungspreis von $120,26 pro Aktie aus und verkaufte die resultierenden Aktien in Open-Market-Transaktionen.

Verkäufe am 27.10 waren 1.000 Aktien zu $411,9545, 1.814 zu $414,4191 und 1.186 zu $420,2887. Verkäufe am 28.10 waren 1.991 zu $413,5798, 509 zu $415,02 und 1.500 zu $417,915. Nach diesen Transaktionen belief sich der direkte Anteil auf 130 Aktien. Indirekte Anteile umfassen 166 durch den Ehepartner, 324.518 und 257.117 durch Familienstiftungen sowie 45.596 und 15.962 über Ehepartner-bezogene Trusts.

Die Einreichung besagt, dass der 10b5-1-Plan am 2. Mai 2025 abgeschlossen wurde und bis zum früheren der beiden Ereignisse fortgeführt wird: Auslaufen eines Tranches von 294.000 Optionen, fällig am 15. März 2026, oder 31. Dezember 2025.

United Therapeutics (UTHR) قد أبلغت عن معاملات داخلية من قبل رئيسها ومهندسها التنفيذي بموجب خطة Rule 10b5-1. في 27/10/2025 و28/10/2025، قام الداخل بتمرين 4,000 خيار أسهم كل يوم عند سعر ممارسة قدره $120.26 للسهم وباع الأسهم الناتجة في معاملات في السوق المفتوح.

كانت المبيعات في 27/10 1,000 سهم بسعر $411.9545، و1,814 بسعر $414.4191، و1,186 بسعر $420.2887. وكانت مبيعات 28/10 1,991 بسعر $413.5798، و509 بسعر $415.02، و1,500 بسعر $417.915. بعد هذه المعاملات، لم يعد يمتلك الأسهم بشكل مباشر 130 سهماً. وتتضمن الملكيات غير المباشرة 166 من قبل الزوج، و324,518 و257,117 عن طريق trusts العائلية، و45,596 و15,962 عبر trusts متعلقة بالزوج.

تنص الوثيقة على أن خطة 10b5-1 تم دخولها في 2 مايو 2025 وستستمر حتى إما نفاد شريحة من 294,000 خيار منتهية صلاحيتها في 15 مارس 2026 أو 31 ديسمبر 2025، أيهما يأتي أولاً.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ROTHBLATT MARTINE A

(Last) (First) (Middle)
C/O UNITED THERAPEUTICS CORPORATION
1000 SPRING STREET

(Street)
SILVER SPRING MD 20910

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chairperson & CEO
3. Date of Earliest Transaction (Month/Day/Year)
10/27/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/27/2025 M(1) 4,000 A $120.26 4,130 D
Common Stock 10/27/2025 S(1) 1,000 D $411.9545(2) 3,130 D
Common Stock 10/27/2025 S(1) 1,814 D $414.4191(3) 1,316 D
Common Stock 10/27/2025 S(1) 1,186 D $420.2887(4) 130 D
Common Stock 10/28/2025 M(1) 4,000 A $120.26 4,130 D
Common Stock 10/28/2025 S(1) 1,991 D $413.5798(5) 2,139 D
Common Stock 10/28/2025 S(1) 509 D $415.02 1,630 D
Common Stock 10/28/2025 S(1) 1,500 D $417.915(6) 130 D
Common Stock 166 I by Spouse
Common Stock 324,518 I by Trust(7)
Common Stock 257,117 I by Trust(8)
Common Stock 45,596 I by Spouse(9)
Common Stock 15,962 I by Spouse(10)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option $120.26 10/27/2025 M(1) 4,000 03/15/2016 03/15/2026 Common Stock 4,000 $0.00 150,000 D
Stock Option $120.26 10/28/2025 M(1) 4,000 03/15/2016 03/15/2026 Common Stock 4,000 $0.00 146,000 D
Explanation of Responses:
1. This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025. This plan will continue until the earlier of: (a) exhaustion of a tranche of 294,000 stock options that expire March 15, 2026; or (b) December 31, 2025.
2. This transaction was executed in multiple trades at prices ranging from $411.92 to $412.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. This transaction was executed in multiple trades at prices ranging from $414.02 to $414.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. This transaction was executed in multiple trades at prices ranging from $420.04 to $420.63. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
5. This transaction was executed in multiple trades at prices ranging from $413.15 to $413.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
6. This transaction was executed in multiple trades at prices ranging from $417.705 to $418.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
7. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
8. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
9. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
10. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
Remarks:
/s/ John S. Hess, Jr. under Power of Attorney 10/30/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
United Therapeutics Corp.

NASDAQ:UTHR

UTHR Rankings

UTHR Latest News

UTHR Latest SEC Filings

UTHR Stock Data

19.53B
42.26M
1.77%
99.51%
5.97%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
SILVER SPRING